BioCentury | Aug 15, 2016
Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
BioCentury | Jul 11, 2016
Clinical News

SB061: Phase I/II started

Symic and Nordic Bioscience began the double-blind, placebo-controlled, Estonian Phase I/II MODIFY-OA trial to evaluate intra-articular injections of SB061 in about 90 patients. In 2015, Symic and Nordic partnered to develop SB061. Nordic Bioscience A/S...
BioCentury | Apr 7, 2016
Product R&D

Branching out

With its second compound about to hit the clinic and a fresh influx of money, Symic Biomedical Inc. is lining up the next three preclinical programs for its extracellular matrix (ECM)-targeting technology. By applying each...
BioCentury | Jan 14, 2016
Company News

Management tracks

Rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) hired Mary Szela as CEO. Sandford Smith had been interim CEO since Marc Beer's resignation in July 2015. Szela was CEO of Melinta Therapeutics Inc. (New Haven, Conn.)....
BioCentury | Dec 11, 2015
Company News

Management tracks

Diagnostic play Natera Inc. (NASDAQ:NTRA) hired Michael Little as SVP of R&D. Little was global head of diagnostics development at Novartis AG (NYSE:NVS; SIX:NOVN). Cancer play Ignyta Inc. (NASDAQ:RXDX) hired William McCarthy as CBO. He...
BioCentury | Dec 7, 2015
Financial News

Symic Biomedical completes venture financing

Symic Biomedical Inc. , San Francisco, Calif. Business: Autoimmune, Cardiovascular Date completed: 2015-12-01 Type: Venture financing Raised: $25 million Investors: Lilly Ventures; Alexandria Real Estate Equities; Purdue Research Foundation; Den Danske Forskiningsfond; Mitsui Global Investment; Ally...
BioCentury | Dec 2, 2015
Financial News

Symic raises $25M in series A-2 round

Symic Biomedical Inc. (San Francisco, Calif.) raised $25 million in a series A-2 round led by existing investor Lilly Ventures. New investors Alexandria Real Estate and Purdue Research Foundation also participated, as did existing investors...
BioCentury | Nov 9, 2015
Clinical News

SB-030: Phase I/II started

Symic began the double-blind, placebo-controlled, international Phase I/II SHIELD trial to evaluate balloon angioplasty with or without single doses of locally applied SB-030 in about 66 patients undergoing procedures for stenosis or occlusion within the...
BioCentury | Sep 21, 2015
Finance

Hedging in Asia

Ally Bridge Group expects its newest investment vehicle - an Asia-focused healthcare hedge fund - will have a surplus of buying opportunities given the plunge of the stock market in China. In other territories, such as Taiwan,...
BioCentury | Jan 5, 2015
Financial News

Symic Biomedical completes venture financing

Symic Biomedical Inc. , San Francisco, Calif. Business: Autoimmune, Cardiovascular Date completed: 2014-11-01 Type: Venture financing Raised: $15 million Investors: Lilly Ventures; Den Danske Forskiningsfond; Mitsui Global Investment; Ally Bridge Group; InCube Ventures; Mission Bay Capital...
Items per page:
1 - 10 of 11
BioCentury | Aug 15, 2016
Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
BioCentury | Jul 11, 2016
Clinical News

SB061: Phase I/II started

Symic and Nordic Bioscience began the double-blind, placebo-controlled, Estonian Phase I/II MODIFY-OA trial to evaluate intra-articular injections of SB061 in about 90 patients. In 2015, Symic and Nordic partnered to develop SB061. Nordic Bioscience A/S...
BioCentury | Apr 7, 2016
Product R&D

Branching out

With its second compound about to hit the clinic and a fresh influx of money, Symic Biomedical Inc. is lining up the next three preclinical programs for its extracellular matrix (ECM)-targeting technology. By applying each...
BioCentury | Jan 14, 2016
Company News

Management tracks

Rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) hired Mary Szela as CEO. Sandford Smith had been interim CEO since Marc Beer's resignation in July 2015. Szela was CEO of Melinta Therapeutics Inc. (New Haven, Conn.)....
BioCentury | Dec 11, 2015
Company News

Management tracks

Diagnostic play Natera Inc. (NASDAQ:NTRA) hired Michael Little as SVP of R&D. Little was global head of diagnostics development at Novartis AG (NYSE:NVS; SIX:NOVN). Cancer play Ignyta Inc. (NASDAQ:RXDX) hired William McCarthy as CBO. He...
BioCentury | Dec 7, 2015
Financial News

Symic Biomedical completes venture financing

Symic Biomedical Inc. , San Francisco, Calif. Business: Autoimmune, Cardiovascular Date completed: 2015-12-01 Type: Venture financing Raised: $25 million Investors: Lilly Ventures; Alexandria Real Estate Equities; Purdue Research Foundation; Den Danske Forskiningsfond; Mitsui Global Investment; Ally...
BioCentury | Dec 2, 2015
Financial News

Symic raises $25M in series A-2 round

Symic Biomedical Inc. (San Francisco, Calif.) raised $25 million in a series A-2 round led by existing investor Lilly Ventures. New investors Alexandria Real Estate and Purdue Research Foundation also participated, as did existing investors...
BioCentury | Nov 9, 2015
Clinical News

SB-030: Phase I/II started

Symic began the double-blind, placebo-controlled, international Phase I/II SHIELD trial to evaluate balloon angioplasty with or without single doses of locally applied SB-030 in about 66 patients undergoing procedures for stenosis or occlusion within the...
BioCentury | Sep 21, 2015
Finance

Hedging in Asia

Ally Bridge Group expects its newest investment vehicle - an Asia-focused healthcare hedge fund - will have a surplus of buying opportunities given the plunge of the stock market in China. In other territories, such as Taiwan,...
BioCentury | Jan 5, 2015
Financial News

Symic Biomedical completes venture financing

Symic Biomedical Inc. , San Francisco, Calif. Business: Autoimmune, Cardiovascular Date completed: 2014-11-01 Type: Venture financing Raised: $15 million Investors: Lilly Ventures; Den Danske Forskiningsfond; Mitsui Global Investment; Ally Bridge Group; InCube Ventures; Mission Bay Capital...
Items per page:
1 - 10 of 11